47 results
Page 2 of 3
8-K
EX-99.1
wip9o9l
4 Jun 21
POINT Biopharma Announces First Patients
4:22pm
425
EX-99.1
xk9hvghq612f6 aprw
4 Jun 21
Business combination disclosure
4:20pm
8-K
EX-99.1
2q10zjxqlsf
1 Jun 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
4:32pm
425
EX-99.1
nhso1543v j0t4hj3r
1 Jun 21
Business combination disclosure
4:30pm
S-4/A
0ih729m
30 Apr 21
Registration of securities issued in business combination transactions (amended)
9:53pm
8-K
EX-99.1
07pki
28 Apr 21
POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility
5:13pm
425
EX-99.1
onpzhc
28 Apr 21
Business combination disclosure
5:11pm
S-4
82etzw6ytjda 1tvj0r
22 Mar 21
Registration of securities issued in business combination transactions
9:52pm
8-K/A
EX-2.1
25siix4
18 Mar 21
Financial Statements and Exhibits
9:08am
8-K
EX-99.1
oie83egcqamxw
15 Mar 21
Public Investor Presentation Transcript
5:20pm
425
EX-99.1
ro85z
15 Mar 21
Business combination disclosure
8:20am
8-K
EX-99.1
va9azfgr
15 Mar 21
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
8:19am
10-K
1g8c sof9ka
5 Mar 21
Annual report
8:13am
10-Q
lcsw0
20 Aug 20
Quarterly report
4:15pm
8-K
EX-99.1
ccyt76wfubz8
16 Jul 20
Report of Independent Registered Public Accounting Firm
4:30pm
8-K
EX-99.1
032rn0 sda
10 Jul 20
Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Pricing of Upsized $118 Million Initial Public Offering
5:17pm